NCT07819539Completed
Anthocyanin-Rich Berry Supplementation in Patients With Colorectal Cancer
Effect of Anthocyanins on the Immune Response During Colorectal Cancer Treatment in Patients Over 65 Years of Age Using Freeze-Dried Black Raspberry and Strawberry Extracts
Source: ClinicalTrials.gov · Last updated 15 Sept 2026
Brief summary (registry, in English)
This prospective, open-label interventional study evaluated the effects of short-term supplementation with an anthocyanin-rich freeze-dried black raspberry and strawberry preparation in patients undergoing treatment for colorectal cancer. The study assessed the tolerability of the intervention and longitudinal changes in nutritional status and selected inflammatory and biochemical biomarkers. Participants received the anthocyanin-rich supplement for 21 consecutive days in addition to standard oncological treatment and were assessed at baseline and during follow-up.
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 70 (actual)
- First submitted
- 9 Sept 2026
- Start date
- 24 May 2023
- Primary completion date
- 1 Dec 2025
- Lead sponsor
- Jagiellonian University
- Diseases
- Colorectal cancer
- NCT number
- NCT07819539
What you commit to
- Study type: Interventional
- Participants enrolled: 70
- From 24 May 2023 to the primary completion date, 1 Dec 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- (1) gastrointestinal obstruction; (2) advanced cardiac or respiratory failure; (3) severe renal or hepatic insufficiency; and (4) food allergies or hypersensitivity that could interfere with administration of the study supplement.
Who the study is looking for
- (1) histologically confirmed primary colorectal adenocarcinoma; (2) qualification for surgical treatment, neoadjuvant chemoradiotherapy, or systemic chemotherapy; (3) ability to receive oral supplementation; and (4) Eastern Cooperative Oncology Group (ECOG) performance status ≤2. (5)Age ≥65 years
Age in the registry: 65 years to - · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Tarnów Oncology Centre Coordinator of this site? Confirm its status | Tarnów | Poland | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.